PTPRR — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL15575767	1.00	1/20
SCHEMBL15575439	0.81	1/20
SCHEMBL15617103	0.81	1/20
SCHEMBL15575996	0.79	1/20
SCHEMBL15617153	0.78	1/20
SCHEMBL15575504	0.78	1/20
SCHEMBL15617120	0.78	1/20
SCHEMBL15617110	0.76	1/20
SCHEMBL15575499	0.76	1/20
SCHEMBL15617092	0.75	1/20
SCHEMBL15617109	0.75	1/20
SCHEMBL15617118	0.74	1/20
SCHEMBL15575443	0.72	1/20
SCHEMBL15617106	0.72	1/20
SCHEMBL30065644	0.72	1/20
Hydrochloric Acid (SCHEMBL29921361)	0.71	1/20
SCHEMBL15617154	0.69	1/20
SCHEMBL15617098	0.68	1/20
SCHEMBL15617089	0.68	1/20
SCHEMBL15617087	0.67	1/20

Clinical trials — most relevant to PTPRR by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Pegylated-Interferon and Ribavirin Plus Metformin in the Treatment of Chronic HCV Infection and Insulin Resistance	PHASE4	UNKNOWN
Regulatory Lymphocytes in Patients Treated With Specific Immunotherapy	PHASE4	COMPLETED
Use of Selective JAK Inhibitor in ILD and Skin Tightness of Systemic Sclerosis Versus MMF	PHASE3	COMPLETED
A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia	PHASE3	RECRUITING
Imatinib in Dermatofibrosarcoma Protuberans (DFSP)	PHASE1/PHASE2	COMPLETED
Pembrolizumab Plus Enfortumab Vedotin in Collecting Duct and Renal Medullary Carcinoma	PHASE2	RECRUITING
Pembrolizumab and Induction Chemotherapy in Head and Neck Squamous Cell Carcinoma (PICH Study)	PHASE1/PHASE2	WITHDRAWN
Study in Adult Ph-positive ALL	PHASE2	UNKNOWN
Temsirolimus With or Without Megestrol Acetate and Tamoxifen Citrate in Treating Patients With Advanced, Persistent, or Recurrent Endometrial Cancer	PHASE2	COMPLETED
Pembrolizumab (MK-3475) in MM Patients With Residual Disease	PHASE2	COMPLETED
Lapatinib Ditosylate in Treating Patients With Unresectable Liver or Biliary Tract Cancer	PHASE2	COMPLETED
Study Assessing Potential Predictive Tumor Markers in Metastatic Colorectal Cancer	PHASE2	COMPLETED
Study Evaluating Toxicity & Efficacy of Lenalidomide(Revlimid®)in Chemotherapy-Naïve AIPC Patients	PHASE2	COMPLETED
Cyclosporine For The Treatment Of COVID-19(+)	PHASE2	COMPLETED
Phase I Study of SC-43 Oral Solution in Subjects With Refractory Solid Tumors	PHASE1	WITHDRAWN
Study of a c-Met Inhibitor PLB1001 in Patients With PTPRZ1-MET Fusion Gene Positive Recurrent High-grade Gliomas	PHASE1	COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma	PHASE1	COMPLETED
Bioequivalence Study of Tacrolimus in Healthy Volunteers	PHASE1	COMPLETED
Study of CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults w/ Recurrent or Refractory B Cell Malignancies	PHASE1	ACTIVE_NOT_RECRUITING
Lymphoid Tyrosine Phosphatase Gene Polymorphisms in Inflammatory Bowel Disease	nan	UNKNOWN
Monitoring of Breathing Effort Through Pressure Time Product Measurement Using Airway Occlusion Pressure	nan	UNKNOWN
C-X-C Chemokine Receptor 4 in Chronic Lymphocytic Leukemia	nan	UNKNOWN
Avapritinib in the Treatment of Unresectable or Recurrent Metastatic GIST Non-exon18 Mutations of PDGFRA	nan	RECRUITING
Role of NFKBIA and PTPN22 Genes Polymorphism in Acute Rejection Susceptibility After Living Donor Liver Transplantation in Egyptian Patients.	nan	COMPLETED
Expression of CD19 Complex in Lymphoproliferative Disorders	nan	UNKNOWN
The Effect Of DAAs on miRNA-122 And Insulin Resistance In Chronic HCV Patients	nan	UNKNOWN
Cardiovascular Effects of Empagliflozine	nan	UNKNOWN
Prospective Monocentric Clinical-biological Database	nan	RECRUITING
Ruxolitinib in Patients With Myelofibrosis	nan	UNKNOWN
Studies of the Tumour Suppressor Gene PTEN - Endometrial Cancer	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a PTPRR binder may also engage these)

Protein	Name	Similarity
Q62132	—	1.000	Q62132 →
O08617	—	1.000	O08617 →
PTPRM	Receptor-type tyrosine-protein phosphatase mu	0.993	landscape →
Q7Z401	—	0.992	Q7Z401 →
Q8AXC7	—	0.992	Q8AXC7 →
A8E7C5	—	0.991	A8E7C5 →
Q9DDT2	—	0.990	Q9DDT2 →
O12990	—	0.990	O12990 →
Q8BMD7	—	0.990	Q8BMD7 →
Q9Y2H2	—	0.990	Q9Y2H2 →
Q9Z2R9	—	0.990	Q9Z2R9 →
PTPN5	Tyrosine-protein phosphatase non-receptor type 5	0.990	landscape →
Q00495	—	0.990	Q00495 →
Q761X5	—	0.990	Q761X5 →
D3YWQ0	—	0.990	D3YWQ0 →
Q8K3E5	—	0.990	Q8K3E5 →
P04157	—	0.989	P04157 →
Q95LP3	—	0.989	Q95LP3 →
Q8BX57	—	0.989	Q8BX57 →
Q9D3R6	—	0.989	Q9D3R6 →
P25799	—	0.989	P25799 →
G5EFD2	—	0.989	G5EFD2 →
DHX29	ATP-dependent RNA helicase DHX29	0.989	landscape →
P35546	—	0.989	P35546 →
KDM5B	Lysine-specific demethylase 5B	0.989	landscape →
Q9H1H9	—	0.989	Q9H1H9 →
Q8JFR5	—	0.989	Q8JFR5 →
Q20402	—	0.989	Q20402 →
Q60629	—	0.989	Q60629 →
TRPV1	Transient receptor potential cation channel subfamily V member 1	0.989	landscape →